STAAR Surgical Company
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $1.45B |
| Revenue | $290M |
| Net Income | $-21M |
| Total Assets | $451M |
| Net Assets | $352M |
| Employees | 921 |
| Value | |
| P/B | 4.11x |
| P/S | 4.99x |
| EV/EBITDA | 91.60x |
| FCF Yield | -3.79% |
| Profitability | |
| ROE | -5.97% |
| ROA | -4.66% |
| Op. Margin | -1.72% |
| Revenue Growth | 119.59% |
| Financial Health | |
| Debt Ratio | 28.03% |
| Total Debt | $37M |
| FCF | $-55M |
| Cash | $132M |
| Current Ratio | 5.12x |
| Net Debt/EBITDA | -6.39x |
| Dividend | |
| Div. Yield | 0.00% |
| Payout Ratio | 0.00% |
| Performance | |
| 1Y Return | 72.82% |
| 1M Return | -10.67% |
| From 52W High | -18.82% |
| 1Y MDD | -43.65% |
| Trading | |
| Volume | 739,653 shares |
| Trading Value | $21M |
| Per Share | |
| EPS | $-1.96 |
| BPS | $6.97 |
Company Info
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.